• In recent days, Merck reported Q2 2026 results with sales rising to US$16.61 billion and updated 2026 revenue guidance to US$66.3–US$67.3 billion, while also announcing regulatory momentum around KEYTRUDA’s new bladder cancer use in Canada and ENFLONSIA’s proposed expanded RSV indication in the US and EU.
• These developments highlight how Merck is leaning on oncology and vaccine innovations to support its earnings outlook amid acquisition-related losses and a complex late-stage pipeline.
• We’ll now consider how this combination of stronger guidance and new RSV and oncology indications could reshape Merck’s investment narrative.

Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

Merck Investment Narrative Recap

To own Merck today, you need to be comfortable with a story built around oncology and vaccines, plus a much larger late‑stage pipeline, while accepting acquisition‑driven losses and an eventual KEYTRUDA patent expiry as core risks. The latest revenue upgrade to US$66.3–US$67.3 billion and new KEYTRUDA and ENFLONSIA regulatory steps support the near term earnings and pipeline catalyst, but do not remove the concentration risk in KEYTRUDA or broader pricing and competition pressures.

The most relevant recent development is the FDA and EMA accepting applications to expand ENFLONSIA’s RSV use into high‑risk children through their second season. That fits directly into the “20 new growth drivers” catalyst, adding another potential pediatric vaccine use case alongside newer launches like CAPVAXIVE. While the decision is not due until 2027, it underlines how Merck is trying to build vaccine and infectious disease pillars that can matter more once KEYTRUDA faces loss of exclusivity.

Yet, while these updates are encouraging, you should also be aware that incoming biosimilar and pricing pressure on KEYTRUDA could...

Merck's narrative projects $74.6 billion revenue and $22.3 billion earnings by 2029.

Uncover how Merck's forecasts yield a $132.78 fair value, a 3% upside to its current price.

Exploring Other Perspectives

Some of the more pessimistic analysts were assuming only about 3 percent annual revenue growth and US$22.0 billion of earnings by 2029, so compared with the current focus on new oncology and RSV catalysts, you can see how views on Keytruda reliance and future pricing could shift quite a bit as this latest news gets absorbed.

Explore 8 other fair value estimates on Merck - why the stock might be worth as much as 64% more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Merck research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Merck research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Merck's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.